News & Views

The Gap Is Where The Pain Is: Drug Pricing and Patient Cost...
Going into 2024, Treehill expects an even greater degree of scrutiny by boards and investors on the merits of deploying capital from the dwindling cash reserves to conducting clinical studies...
Treehill Partners featured amongst prominent KOLs in Part 2 of Scrip's 2024 biopharma outlook interview, discussing funding environment, M&A, and partnering...
Chinese biotech's advance has been as ferocious as the nation's breakthrough efforts in AI and EVs, eclipsing the EU and catching up to the US...
Companies are being asked to take-on increasingly complex challenges in an environment where there are diminished resources...
Mandy Jackson, US editor of Citeline's Scrip, has published the below interview with Ali Pashazadeh, Treehill Partners CEO...
At this year's BIO Convention in Boston, Ali Pashazadeh, Treehill Partners CEO, spoke with Manasee Kurlekar, BioSpectrum Asia Chief Executive Officer...
At PCMG Clinical Outsourcing Community today, Ali Pashazadeh, Treehill Partners CEO, was giving a podium presentation on "A view from the top - how will Clinical Development Outsourcing adapt to a rapidly changing landscape"...
Whilst outsourcing of drug development and manufacturing is an attempt to undertake purposeful action in a web of interdependent contingencies, this interview with Ali Pashazadeh, Treehill Partners CEO...
Outsourced Pharma Chief Editor Louis Garguilo has interviewed Ali Pashazadeh, Treehill Partners CEO, to help think through the evolving U.S. policies and tariff turbulance as they relate to the outsourcing of development and manufacturing...
The Pink Sheet and Citeline have just published their summary article 'Quotable: Top Experts on Policy Hot Topics’, picking out 12 recent articles that are ‘must read’....
From Ali Pashazadeh’s perspective, many trials fail because of how they are designed. And as the CEO of financial advisory firm Treehill Partners, he has a plan to solve that...

Subscribe to our mailings!

Thank You

Please choose your subscriptions:

Unsubscribe any time using the footer of our emails. For information about our privacy practices, please visit our privacy policy.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.